Physician profile
Jocelyn E Larocque
NPI 1831178631
$5,726.22
in general payments reported to CMS, 2019-2025
26 companies · $672 in 2025
The $672 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $293 · 2021: $197 · 2022: $893 · 2023: $1,166 · 2024: $1,593 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.98 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.66 | 2019-2025 | |
| Genzyme Corporation | $876.53 | 2019-2024 | |
| Pfizer INC. | $528.98 | 2019-2025 | |
| Janssen Biotech, INC. | $416.88 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $346.36 | 2019-2025 | |
| Lilly USA, LLC | $344.66 | 2019-2024 | Olumiant, Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $289.41 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $269.17 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $265.48 | 2019-2023 | Adbry |
| Amgen INC. | $185.55 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $147.34 | 2019-2024 | Aklief, Oracea, Epsolay |
| Ucb, INC. | $136.95 | 2019-2025 | Bimzelx |
| Celgene Corporation | $113.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.42 | 2022-2024 | Spevigo |
| Tempus Ai, INC | $93.70 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $83.82 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $77.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $73.85 | 2024 | Dupixent |
| Botanix Sb INC | $57.98 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $32.48 | 2020-2022 | |
| Mission Pharmacal Company | $27.69 | 2019-2022 | |
| Almirall LLC | $22.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.41 | 2025 | Cabtreo |
| Dermira, INC. | $18.56 | 2020 | |
| Dermavant Sciences, INC. | $17.99 | 2023 | Vtama |
| Epi Health, LLC | $10.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Larocque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.